Pharmaceutical

GUB-014295 by Gubra for Obesity: Likelihood of Approval

GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.

Dec 20, 2023 - 18:00
GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.
Read the original article

Tags:

Previous Article

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

Next Article

Meloxicam fast acting by Viatris for Post-Operative Pain: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA clears PK Med to streamline gout injectable to Phase II

FDA clears PK Med to streamline gout injectable to Phas...

Feb 26, 2024

Medication Adherence Solutions for the Pharmaceutical Industry

Medication Adherence Solutions for the Pharmaceutical I...

Oct 2, 2024

STAT+: 4 ways the health care system should shift its thinking on AI, according to experts

STAT+: 4 ways the health care system should shift its t...

May 5, 2023